FDA Approves Lytenava (bevacizumab-vikg) for the Treatment of Wet Age-Related Macular Degeneration

Дата публикации: 24-07-2026 00:07:18

ISELIN, N.J., July 24, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of ONS-5010/Lytenava (bevacizumab-vikg, bevacizumab gamma) for the treatment of...

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Outlook Therapeutics Announces FDA Acceptance of Resubmitted Biologics License Application for ONS-5010/Lytenava (bevacizumab-vikg) as a Treatment for Wet AMD	0	10.76	16-06-2026
2	FDA approves Lytenava for wet AMD	0	9.72	24-07-2026
3	FDA Approves Lumvoa (veligrotug-vvze) for the Treatment of Thyroid Eye Disease	0	18.73	26-06-2026
4	Ocugen Announces that the U.S. Food and Drug Administration Has Granted OCU410 Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of Geographic Atrophy, Secondary to Dry Age-Related Macular Degeneration	0	12.79	29-07-2026
5	Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1	0	13.96	12-06-2026
6	FDA Approves Leqembi Iqlik (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer’s Disease	0	13.38	13-07-2026
7	FDA Approves Tauklarify (florquinitau F 18 injection), an F18-Labeled Tau PET Imaging Agent for Alzheimer’s Disease	0	17.62	14-08-2026
8	FDA Grants Accelerated Approval for Genglycos (pariglasgene brecaparvovec-opnr) Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia	0	13.83	19-08-2026
9	FDA Approves Orzeyful (oveporexton) to Treat the Underlying Cause of Narcolepsy Type 1	0	19.75	05-08-2026
10	FDA Approves Pasatru (garetosmab-grts) for the Treatment of Fibrodysplasia Ossificans Progressiva	0	15.91	19-08-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 16.74. Источник: www.drugs.com.